Inicio
Resultado de la búsqueda
5 búsqueda de la palabra clave 'nephrotic syndrome'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigaciónNephrotic syndrome associated with primary atypical hemolytic uremic syndrome / John Fredy Nieto Ríos
Título : Nephrotic syndrome associated with primary atypical hemolytic uremic syndrome Tipo de documento : documento electrónico Autores : John Fredy Nieto Ríos, Fecha de publicación : 2020 Títulos uniformes : Brazilian Journal of Nephrology Idioma : Inglés (eng) Palabras clave : Atypical Hemolytic Uremic Syndrome Nephrotic Syndrome Acute Renal Injury Hypertension Complement System Proteins Resumen : Primary atypical hemolytic-uremic syndrome is a rare disease characterized by non-immune microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction; it is related to alterations in the regulation of the alternative pathway of complement due to genetic mutations. The association with nephrotic syndrome is unusual. We present here a pediatric patient diagnosed with primary atypical hemolytic-uremic syndrome associated with nephrotic syndrome who responded to eculizumab treatment. Mención de responsabilidad : Diana Carolina Bello-Marquez, John Fredy Nieto-Rios, Lina Maria Serna-Higuita, Alfonso Jose Gonzalez-Vergara Referencia : J Bras Nefrol. Jul-Sep 2021;43(3):440-444. DOI (Digital Object Identifier) : 10.1590/2175-8239-jbn-2020-0050 PMID : 32779691 Derechos de uso : CC BY En línea : https://bjnephrology.org/en/article/nephrotic-syndrome-associated-with-primary-a [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5738 Nephrotic syndrome associated with primary atypical hemolytic uremic syndrome [documento electrónico] / John Fredy Nieto Ríos, . - 2020.
Obra : Brazilian Journal of Nephrology
Idioma : Inglés (eng)
Palabras clave : Atypical Hemolytic Uremic Syndrome Nephrotic Syndrome Acute Renal Injury Hypertension Complement System Proteins Resumen : Primary atypical hemolytic-uremic syndrome is a rare disease characterized by non-immune microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction; it is related to alterations in the regulation of the alternative pathway of complement due to genetic mutations. The association with nephrotic syndrome is unusual. We present here a pediatric patient diagnosed with primary atypical hemolytic-uremic syndrome associated with nephrotic syndrome who responded to eculizumab treatment. Mención de responsabilidad : Diana Carolina Bello-Marquez, John Fredy Nieto-Rios, Lina Maria Serna-Higuita, Alfonso Jose Gonzalez-Vergara Referencia : J Bras Nefrol. Jul-Sep 2021;43(3):440-444. DOI (Digital Object Identifier) : 10.1590/2175-8239-jbn-2020-0050 PMID : 32779691 Derechos de uso : CC BY En línea : https://bjnephrology.org/en/article/nephrotic-syndrome-associated-with-primary-a [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5738 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001677 AC-2020-148 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-148Adobe Acrobat PDF
Título : Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children Tipo de documento : documento electrónico Autores : Gloria Patricia Monsalve Arias, Fecha de publicación : 2017 Títulos uniformes : Journal of The American Society of Nephrology Idioma : Inglés (eng) Palabras clave : Children immunosuppression nephrotic syndrome outcomes podocytopathies steroid resistance Resumen : We investigated the value of genetic, histopathologic, and early treatment response information in prognosing long-term renal outcome in children with primary steroid-resistant nephrotic syndrome. From the PodoNet Registry, we obtained longitudinal clinical information for 1354 patients (disease onset at >3 months and Mención de responsabilidad : Agnes Trautmann, Sven Schnaidt, Beata S Lipska-Ziętkiewicz, Monica Bodria, Fatih Ozaltin, Francesco Emma, Ali Anarat, Anette Melk, Marta Azocar, Jun Oh, Bassam Saeed, Alaleh Gheisari, Salim Caliskan, Jutta Gellermann, Lina Maria Serna Higuita, Augustina Jankauskiene, Dorota Drozdz, Sevgi Mir, Ayse Balat, Maria Szczepanska, Dusan Paripovic, Alexandra Zurowska, Radovan Bogdanovic, Alev Yilmaz, Bruno Ranchin, Esra Baskin, Ozlem Erdogan, Giuseppe Remuzzi, Agnieszka Firszt-Adamczyk, Elzbieta Kuzma-Mroczkowska, Mieczyslaw Litwin, Luisa Murer, Marcin Tkaczyk, Helena Jardim, Anna Wasilewska, Nikoleta Printza, Kibriya Fidan, Eva Simkova, Halina Borzecka, Hagen Staude, Katharina Hees, Franz Schaefer, PodoNet Consortium Referencia : J Am Soc Nephrol. 2017 Oct;28(10):3055-3065. DOI (Digital Object Identifier) : 10.1681/ASN.2016101121 PMID : 28566477 En línea : https://jasn.asnjournals.org/content/28/10/3055.long Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4079 Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children [documento electrónico] / Gloria Patricia Monsalve Arias, . - 2017.
Obra : Journal of The American Society of Nephrology
Idioma : Inglés (eng)
Palabras clave : Children immunosuppression nephrotic syndrome outcomes podocytopathies steroid resistance Resumen : We investigated the value of genetic, histopathologic, and early treatment response information in prognosing long-term renal outcome in children with primary steroid-resistant nephrotic syndrome. From the PodoNet Registry, we obtained longitudinal clinical information for 1354 patients (disease onset at >3 months and Mención de responsabilidad : Agnes Trautmann, Sven Schnaidt, Beata S Lipska-Ziętkiewicz, Monica Bodria, Fatih Ozaltin, Francesco Emma, Ali Anarat, Anette Melk, Marta Azocar, Jun Oh, Bassam Saeed, Alaleh Gheisari, Salim Caliskan, Jutta Gellermann, Lina Maria Serna Higuita, Augustina Jankauskiene, Dorota Drozdz, Sevgi Mir, Ayse Balat, Maria Szczepanska, Dusan Paripovic, Alexandra Zurowska, Radovan Bogdanovic, Alev Yilmaz, Bruno Ranchin, Esra Baskin, Ozlem Erdogan, Giuseppe Remuzzi, Agnieszka Firszt-Adamczyk, Elzbieta Kuzma-Mroczkowska, Mieczyslaw Litwin, Luisa Murer, Marcin Tkaczyk, Helena Jardim, Anna Wasilewska, Nikoleta Printza, Kibriya Fidan, Eva Simkova, Halina Borzecka, Hagen Staude, Katharina Hees, Franz Schaefer, PodoNet Consortium Referencia : J Am Soc Nephrol. 2017 Oct;28(10):3055-3065. DOI (Digital Object Identifier) : 10.1681/ASN.2016101121 PMID : 28566477 En línea : https://jasn.asnjournals.org/content/28/10/3055.long Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4079 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000688 AC-2017-077 Archivo digital Producción Científica Artículos científicos Disponible
Título : Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis Tipo de documento : documento electrónico Autores : Luis Fernando Pinto Peñaranda, ; Javier Darío Márquez Hernández, ; Carolina Muñoz Grajales, ; Carlos Jaime Velásquez Franco, Fecha de publicación : 2015 Títulos uniformes : Clinical Rheumatology Idioma : Inglés (eng) Palabras clave : Latin American mestizo lupus nephritis nephrotic syndrome proteinuria remission induction Resumen : The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12 months in a group of patients with proliferative lupus nephritis from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with systemic lupus erythematosus as defined by the American College of Rheumatology with biopsy-proven nephritis. We assessed 149 patients, with 84 % female. Age at diagnosis of systemic lupus erythematosus is 24.7 years (16–31). The time between diagnosis of lupus erythematosus and proliferative nephritis is 2 months (0–35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8 %), III (13.4 %), V + III (3.3 %), and V + IV (3.3 %). Activity index is 6.18 ± 4.55 and chronicity index is 1 (0–3). The result of 24-h proteinuria is 2000 mg (667–4770) and baseline creatinine is 0.9 mg/dL (0.7–1.3). Induction therapy includes corticosteroids (100 %), cyclophosphamide (74.1 %), and mycophenolate mofetil (25.9 %). At 12 months, 40.7 % of individuals failed to attain partial or complete remission. Elevated creatinine (p = 0.0001) and 24-h proteinuria greater than 1500 mg (p = 0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline creatinine elevation (OR 3.62, 95 % CI, 1.59–8.23; p = 0.002) and 24-h proteinuria greater than 1500 mg (OR 3.62, 95 % CI, 1.29–10.13; p = 0.014) were independent predictors of failure to achieve partial or complete remission. At 12 months, 40.7 % of patients did not attain partial or complete remission. Baseline elevated creatinine and 24-h proteinuria over 1500 mg were predictors for poor response. Mención de responsabilidad : Luis Fernando Pinto-Peñaranda, Vladimir Duque-Caballero, Javier Darío Márquez-Hernández, Carolina Muñoz-Grajales, Carlos Jaime Velásquez-Franco Referencia : Clin Rheumatol. 2015 May;34(5):897-903. DOI (Digital Object Identifier) : 10.1007/s10067-015-2864-7 PMID : 25592376 En línea : https://link.springer.com/article/10.1007%2Fs10067-015-2864-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3887 Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis [documento electrónico] / Luis Fernando Pinto Peñaranda, ; Javier Darío Márquez Hernández, ; Carolina Muñoz Grajales, ; Carlos Jaime Velásquez Franco, . - 2015.
Obra : Clinical Rheumatology
Idioma : Inglés (eng)
Palabras clave : Latin American mestizo lupus nephritis nephrotic syndrome proteinuria remission induction Resumen : The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12 months in a group of patients with proliferative lupus nephritis from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with systemic lupus erythematosus as defined by the American College of Rheumatology with biopsy-proven nephritis. We assessed 149 patients, with 84 % female. Age at diagnosis of systemic lupus erythematosus is 24.7 years (16–31). The time between diagnosis of lupus erythematosus and proliferative nephritis is 2 months (0–35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8 %), III (13.4 %), V + III (3.3 %), and V + IV (3.3 %). Activity index is 6.18 ± 4.55 and chronicity index is 1 (0–3). The result of 24-h proteinuria is 2000 mg (667–4770) and baseline creatinine is 0.9 mg/dL (0.7–1.3). Induction therapy includes corticosteroids (100 %), cyclophosphamide (74.1 %), and mycophenolate mofetil (25.9 %). At 12 months, 40.7 % of individuals failed to attain partial or complete remission. Elevated creatinine (p = 0.0001) and 24-h proteinuria greater than 1500 mg (p = 0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline creatinine elevation (OR 3.62, 95 % CI, 1.59–8.23; p = 0.002) and 24-h proteinuria greater than 1500 mg (OR 3.62, 95 % CI, 1.29–10.13; p = 0.014) were independent predictors of failure to achieve partial or complete remission. At 12 months, 40.7 % of patients did not attain partial or complete remission. Baseline elevated creatinine and 24-h proteinuria over 1500 mg were predictors for poor response. Mención de responsabilidad : Luis Fernando Pinto-Peñaranda, Vladimir Duque-Caballero, Javier Darío Márquez-Hernández, Carolina Muñoz-Grajales, Carlos Jaime Velásquez-Franco Referencia : Clin Rheumatol. 2015 May;34(5):897-903. DOI (Digital Object Identifier) : 10.1007/s10067-015-2864-7 PMID : 25592376 En línea : https://link.springer.com/article/10.1007%2Fs10067-015-2864-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3887 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000467 AC-2015-020 Archivo digital Producción Científica Artículos científicos Disponible
Título : IgM nephropathy in children : clinicopathologic analysis Tipo de documento : documento electrónico Autores : Catalina Vélez Echeverri, ; Lina Maria Serna Higuita, ; Carolina Lucía Ochoa García, ; Juan José Vanegas Ruiz, Fecha de publicación : 2013 Títulos uniformes : Nefrología Idioma : Inglés (eng) Palabras clave : Minimal change disease glomerular diseases focal segmental glomeruloesclerosis nephrotic syndrome IgM nephropathy Resumen : Introduction: IgM nephropathy (IgMN) is a glomerulonephritis characterised by diffuse mesangial immunoglobulin M (IgM) deposits. It usually presents with nephrotic range proteinuria and, according to some previous work, it occurs most often in patients who are resistant to or dependent on steroid treatment. Objective: To perform a clinical, histological and immunopathological description and assess the response to steroid treatment of paediatric patients diagnosed with nephrotic syndrome and diffuse mesangial IgM deposits. Method: This is a descriptive, retrospective study carried out in two hospitals, where the clinical records of paediatric patients with IgMN were analysed and the histological sections were re-assessed. Results: thirteen children were included in this study. IgMN corresponded to 5.17% of all paediatric renal biopsies. The age of patients ranged from 1 year to 12 years (median: 2 years), 46.7% were women. The most common morphological finding was diffuse mesangial hypercellularity (46.1%), followed by focal segmental glomerulosclerosis (30.8%) and minimal glomerular changes (23.1%). All patients received steroids; in 4 cases (30.7%) as the only immunosuppressant medication, 3 (23.1%) also received cyclophosphamide, 5 (38.4%) mycophenolate, and 1 (7.7%) cyclosporine. Seven patients (53.8%) had frequent relapses, 5 (38.5%) were cortico-resistant and 1 (7.7%) cortico-dependent. Two patients (15.38%) had chronic impairment of renal function. Conclusion: The presence of diffuse mesangial IgM in paediatric patients with nephrotic syndrome is not a very uncommon finding; its clinical presentation has been associated with lower response to steroids. However, the long-term prognosis of these patients is still unknown. Mención de responsabilidad : Luis F Arias, M Claudia Prada, Catalina Vélez-Echeverri, Lina M Serna-Higuita, Ana K Serrano-Gayubo, Carolina L Ochoa, Juan J Vanegas-Ruiz Referencia : Nefrologia. 2013;33(4):532-8. DOI (Digital Object Identifier) : 10.3265/Nefrologia.pre2013.Mar.11962 PMID : 23897185 Derechos de uso : CC BY-NC-ND En línea : https://www.revistanefrologia.com/en-igm-nephropathy-in-children-clinicopatholog [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3725 IgM nephropathy in children : clinicopathologic analysis [documento electrónico] / Catalina Vélez Echeverri, ; Lina Maria Serna Higuita, ; Carolina Lucía Ochoa García, ; Juan José Vanegas Ruiz, . - 2013.
Obra : Nefrología
Idioma : Inglés (eng)
Palabras clave : Minimal change disease glomerular diseases focal segmental glomeruloesclerosis nephrotic syndrome IgM nephropathy Resumen : Introduction: IgM nephropathy (IgMN) is a glomerulonephritis characterised by diffuse mesangial immunoglobulin M (IgM) deposits. It usually presents with nephrotic range proteinuria and, according to some previous work, it occurs most often in patients who are resistant to or dependent on steroid treatment. Objective: To perform a clinical, histological and immunopathological description and assess the response to steroid treatment of paediatric patients diagnosed with nephrotic syndrome and diffuse mesangial IgM deposits. Method: This is a descriptive, retrospective study carried out in two hospitals, where the clinical records of paediatric patients with IgMN were analysed and the histological sections were re-assessed. Results: thirteen children were included in this study. IgMN corresponded to 5.17% of all paediatric renal biopsies. The age of patients ranged from 1 year to 12 years (median: 2 years), 46.7% were women. The most common morphological finding was diffuse mesangial hypercellularity (46.1%), followed by focal segmental glomerulosclerosis (30.8%) and minimal glomerular changes (23.1%). All patients received steroids; in 4 cases (30.7%) as the only immunosuppressant medication, 3 (23.1%) also received cyclophosphamide, 5 (38.4%) mycophenolate, and 1 (7.7%) cyclosporine. Seven patients (53.8%) had frequent relapses, 5 (38.5%) were cortico-resistant and 1 (7.7%) cortico-dependent. Two patients (15.38%) had chronic impairment of renal function. Conclusion: The presence of diffuse mesangial IgM in paediatric patients with nephrotic syndrome is not a very uncommon finding; its clinical presentation has been associated with lower response to steroids. However, the long-term prognosis of these patients is still unknown. Mención de responsabilidad : Luis F Arias, M Claudia Prada, Catalina Vélez-Echeverri, Lina M Serna-Higuita, Ana K Serrano-Gayubo, Carolina L Ochoa, Juan J Vanegas-Ruiz Referencia : Nefrologia. 2013;33(4):532-8. DOI (Digital Object Identifier) : 10.3265/Nefrologia.pre2013.Mar.11962 PMID : 23897185 Derechos de uso : CC BY-NC-ND En línea : https://www.revistanefrologia.com/en-igm-nephropathy-in-children-clinicopatholog [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3725 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000298 AC-2013-066 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2013-066.pdfAdobe Acrobat PDF
Título : Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience Tipo de documento : documento electrónico Autores : Catalina Vélez Echeverri, ; Gustavo Adolfo Zuluaga Valencia, ; Lina Maria Serna Higuita, ; John Jairo Zuleta Tobón, ; Juan José Vanegas Ruiz, Fecha de publicación : 2013 Títulos uniformes : Brazilian Journal of Nephrology Idioma : Inglés (eng) Palabras clave : Immunosuppressive Agents Chronic Kidney Failure mycophenolic acid Nephrotic Syndrome Resumen : INTRODUCTION: Nephrotic syndrome is one of the most frequent glomerular diseases among children, and steroid therapy remains as the treatment choice. In spite of this, 10 to 15% of the patients are steroidresistant, and the best therapy for such cases has never been defined. Mycophenolate acid (MA) is one of the treatments used in such situations. OBJECTIVE: To describe the clinical behavior of children diagnosed with steroid-resistant nephrotic syndrome (SRNS) and to assess the therapeutic response to MA. METHODS: This was a retrospective and descriptive study. RESULTS: 26 clinical records of patients with SRNS; 70% male and 30% female. All patients underwent kidney biopsies, which showed a predominance of focal segmental glomerulosclerosis (FSGS). The immunosuppresive drugs used were: Mycophenolate mofetil (MMF) 100%, Cyclosporine 69.2%, Cyclophosphamide 23.1%, and Rituximab 23%. One month after treatment initiation with MMF 61.5% achieved remission. The median of relapses per year for the patients was 3 (p25: 2.75 – p75: 4). This median became 1 (p25: 1 – p75: 3.25) after using this medication (p = 0.08). Furthermore, prior to the start of the MMF treatment, the median of the steroid dose was 1 (p25: 0.5- p75: 1.62) mg/k/day. After using MMF, this median became 0.07 (p25: 0 – p75: 0.55) mg/k/day (p Mención de responsabilidad : Catalina Velez Echeverri, Gustavo Adolfo Zuluaga Valencia, Lina Maria Serna Higuita, Ana Katherina Serrano Gayubo, Carolina Lucia Ochoa, Luisa Fernanda Rojas Rosas, Laura Carolina Muñoz, Javier Sierra, Jhon Jairo Zuleta, Juan José Vanegas Ruiz Referencia : J Bras Nefrol. Jul-Sep 2013;35(3):200-5. DOI (Digital Object Identifier) : 10.5935/0101-2800.20130032 PMID : 24100739 Derechos de uso : CC BY En línea : https://bjnephrology.org/en/article/immunosupressive-therapy-in-children-with-st [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4951 Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience [documento electrónico] / Catalina Vélez Echeverri, ; Gustavo Adolfo Zuluaga Valencia, ; Lina Maria Serna Higuita, ; John Jairo Zuleta Tobón, ; Juan José Vanegas Ruiz, . - 2013.
Obra : Brazilian Journal of Nephrology
Idioma : Inglés (eng)
Palabras clave : Immunosuppressive Agents Chronic Kidney Failure mycophenolic acid Nephrotic Syndrome Resumen : INTRODUCTION: Nephrotic syndrome is one of the most frequent glomerular diseases among children, and steroid therapy remains as the treatment choice. In spite of this, 10 to 15% of the patients are steroidresistant, and the best therapy for such cases has never been defined. Mycophenolate acid (MA) is one of the treatments used in such situations. OBJECTIVE: To describe the clinical behavior of children diagnosed with steroid-resistant nephrotic syndrome (SRNS) and to assess the therapeutic response to MA. METHODS: This was a retrospective and descriptive study. RESULTS: 26 clinical records of patients with SRNS; 70% male and 30% female. All patients underwent kidney biopsies, which showed a predominance of focal segmental glomerulosclerosis (FSGS). The immunosuppresive drugs used were: Mycophenolate mofetil (MMF) 100%, Cyclosporine 69.2%, Cyclophosphamide 23.1%, and Rituximab 23%. One month after treatment initiation with MMF 61.5% achieved remission. The median of relapses per year for the patients was 3 (p25: 2.75 – p75: 4). This median became 1 (p25: 1 – p75: 3.25) after using this medication (p = 0.08). Furthermore, prior to the start of the MMF treatment, the median of the steroid dose was 1 (p25: 0.5- p75: 1.62) mg/k/day. After using MMF, this median became 0.07 (p25: 0 – p75: 0.55) mg/k/day (p Mención de responsabilidad : Catalina Velez Echeverri, Gustavo Adolfo Zuluaga Valencia, Lina Maria Serna Higuita, Ana Katherina Serrano Gayubo, Carolina Lucia Ochoa, Luisa Fernanda Rojas Rosas, Laura Carolina Muñoz, Javier Sierra, Jhon Jairo Zuleta, Juan José Vanegas Ruiz Referencia : J Bras Nefrol. Jul-Sep 2013;35(3):200-5. DOI (Digital Object Identifier) : 10.5935/0101-2800.20130032 PMID : 24100739 Derechos de uso : CC BY En línea : https://bjnephrology.org/en/article/immunosupressive-therapy-in-children-with-st [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4951 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001537 AC-2013-161 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2013-161.pdfAdobe Acrobat PDF
